Varanasi News Magazine

DelveInsight’s “CAR T-Cell Therapy Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the CAR T-Cell Therapy pipeline landscape. It covers the CAR T-Cell Therapy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR T-Cell Therapy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the CAR T-Cell Therapy Pipeline? @ https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight

Key Takeaways from the CAR T-Cell Therapy Pipeline Report

• On June 01, 2026- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company initiated a phase 2 study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.
• On May 27, 2026- Novartis Pharmaceuticals announced a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.
• On May 26, 2026- Abramson Cancer Center at Penn Medicine conducted a phase II study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
• On May 22, 2026- AstraZeneca initiated a Phase I/II study will evaluate the safety, tolerability, antitumour activity, cellular kinetics, pharmacodynamics, and immunogenicity of AZD5851 in adult participants with GPC3+ advanced/recurrent HCC, where at least one line of prior therapy has failed/or was intolerable, or participant/investigator decision.
• DelveInsight’s CAR T-Cell Therapy Pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for CAR T-Cell Therapy treatment.
• The leading CAR T-Cell Therapy Companies such as Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Caribou Biosciences, Atara Bio therapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals and others.
• Promising CAR T-Cell Therapy Therapies such as Itacitinib, Cyclophosphamide, Fludarabine, WU-CART-007, Cevostamab, JNJ-68284528, Lenalidomide, Daratumumab, KYV-101, Epcoritamab, and others.

Want to know which companies are leading innovation in CAR T-Cell Therapy? @ CAR T-Cell Therapy Clinical Trials Assessment

The CAR T-Cell Therapy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The CAR T-Cell Therapy Pipeline Report also highlights the unmet needs with respect to the CAR T-Cell Therapy.

CAR T-Cell Therapy Overview

CAR-T cell therapy represents a revolutionary approach in cancer treatment, harnessing the power of the immune system to combat cancer. This cutting-edge therapy involves a meticulous process where a patient’s own T cells, a vital component of the immune system responsible for identifying and eliminating foreign invaders, are genetically engineered to specifically target and destroy cancer cells. The process begins by extracting T cells from the patient’s blood through a process called leukapheresis. Once isolated, these T cells undergo genetic modification in the laboratory. Specifically, scientists introduce a gene encoding a chimeric antigen receptor (CAR) into the T cells. This CAR is designed to recognize and bind to a specific protein expressed on the surface of cancer cells. This customization ensures that the engineered T cells can specifically target and attack cancerous cells while sparing healthy cells.

CAR T-Cell Therapy Emerging Drugs Profile

• Descartes-08: Cartesian Therapeutics

Descartes-08 is an autologous anti-B cell maturation antigen (BCMA) mRNA CAR-T. Compared to conventional DNA-based CAR T-cell therapies, mRNA CAR-T is designed not to require preconditioning chemotherapy, has been observed to have predictable and controllable pharmacokinetics, and is designed to avoid the risk of genomic integration. Descartes-08 has been granted Orphan Drug Designation by the US FDA for the treatment of MG, a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Currently, the drug is in Phase II stage of clinical trial for the treatment of autoimmune disorders.

• KYV-101: Kyverna Therapeutics

KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase 1 trial in oncology. Results were published by the NIH in Nature Medicine3. KYV-101 is currently being evaluated in sponsored, open-label, Phase 1/2 trials of KYV-101 in patients with lupus nephritis, an autoimmune disease in which more than half of patients do not achieve a complete response to current therapies and are at risk of developing kidney failure. Additionally, FDA’s IND clearance has been obtained for Phase 2 trials of KYV-101 for multiple sclerosis and myasthenia gravis, and a Phase I/II trial for systemic sclerosis.

• TX200: Sangamo Therapeutics

TX200 is composed of the patient’s own (autologous) regulatory T cells (Tregs) engineered to express a chimeric antigen receptor (CAR) designed to recognize the HLA-A2 protein present on a transplanted kidney and bind to it. TX200 is in development for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. It is in Phase I/II stage of its clinical trial.

• ALLO-605: Allogene Therapeutics

ALLO-605, a next-generation AlloCAR T™ known as a TurboCAR™, is an investigational product that targets the B-cell maturation antigen (BCMA) for the treatment of patients with relapsed/refractory multiple myeloma and other BCMA-positive malignancies. This study uses ALLO-647, Allogene’s proprietary monoclonal antibody (mAb), as a part of its differentiated lymphodepletion regimen. ALLO-605 incorporates Allogene’s proprietary TurboCAR technology, which allows for cytokine activation signaling to be engineered selectively into CAR T cells. In June 2021, ALLO-605 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed/refractory multiple myeloma. The Phase 1 study evaluating ALLO-605 is underway. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Multiple Myeloma.

• ATA3219: Atara Biotherapeutics

ATA3219 combines the natural biology of unedited T cells with the benefits of an allogeneic therapy. It consists of allogeneic Epstein-Barr virus (EBV)-sensitized T cells that express a CD19 CAR construct for the treatment of CD19+ relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin’s lymphoma and B-cell mediated autoimmune diseases including systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]). ATA3219 has been optimized to offer a potential best-in-class profile, featuring off-the-shelf availability. Currently, the drug is in Phase I stage of its clinical trial.

• CB-010: Caribou Biosciences

CB-010 is an allogeneic anti-CD19 CAR-T cell therapy for the treatment of patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). CB-010 is the first allogeneic CAR-T cell therapy, to our knowledge, in a clinical trial with a PD-1 knockout, a genome-editing strategy designed to improve antitumor activity by limiting premature CAR-T cell exhaustion. CB-010 is being evaluated in the ongoing, open-label, multicenter ANTLER Phase I clinical trial in adults with r/r B-NHL.

If you’re tracking ongoing CAR T-Cell Therapy Clinical trials @ CAR T-Cell Therapy Treatment Drugs

The CAR T-Cell Therapy Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of CAR T-Cell Therapy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR T-Cell Therapy Treatment.
• CAR T-Cell Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• CAR T-Cell Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CAR T-Cell Therapy market.

CAR T-Cell Therapy Companies

Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Caribou Biosciences, Atara Bio therapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals and others.

CAR T-Cell Therapy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

CAR T-Cell Therapy Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the CAR T-Cell Therapy Pipeline Report @ CAR T-Cell Therapy Market Drivers and Barriers, and Future Perspectives

Scope of the CAR T-Cell Therapy Pipeline Report

• Coverage- Global
• CAR T-Cell Therapy Companies- Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Caribou Biosciences, Atara Bio therapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals and others.
• CAR T-Cell Therapy Therapies- Itacitinib, Cyclophosphamide, Fludarabine, WU-CART-007, Cevostamab, JNJ-68284528, Lenalidomide, Daratumumab, KYV-101, Epcoritamab, and others.
• CAR T-Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• CAR T-Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the CAR T-Cell Therapy Treatment landscape in this detailed analysis @ CAR T-Cell Therapy Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. CAR-T: Overview
4. Pipeline Therapeutics
5. Therapeutics Assessment
6. CAR-T– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. Descartes-08: Cartesian Therapeutics
10. Early Stage Products (Phase I)
11. ATA3219: Atara Biotherapeutics
12. Preclinical and Discovery Stage Products
13. Inactive Products
14. CAR-T Key Companies
15. CAR-T Key Products
16. CAR-T- Unmet Needs
17. CAR-T- Market Drivers and Barriers
18. CAR-T- Future Perspectives and Conclusion
19. CAR-T Analyst Views
20. CAR-T Key Companies
21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/car-t-pipeline-insight